Buy Progenics Pharmaceuticals Stock | PGNX Stock Price & Latest News | Public

Progenics Pharmaceuticals

    We couldn’t load this chart.

    Some stock charts might currently not be supported. To try again, please refresh this page.

    About PGNX

    Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate...Read more

    Community

    People who own or watch this stock

    Buy any stock with any amount of money.

    Download the App
    Download the app

    What Wall Street Thinks

    Rating

    What Wall St. analysts suggest for this stock

    1

    Price Targets

    What analysts think this stock will be worth

    $0.00
    current
    $6.50
    average

    Events

    List of events that could affect this stock.

    07May

    Earnings data Q1 2020

    07Aug

    Earnings data Q2 2020

    Earnings

    The value each share was expected to gain vs. the value that each share actually gained

    0
    -0.08
    -0.16
    -0.24
    Q4 2019
    Q1 2020
    Q2 2020
    Q3 2020

    Expected EPS
    Q3 2020

    -$0.24

    Actual EPS
    Q3 2020

    Stats

    Market Cap$355,04M
    Volume
    Price-to-Earnings Ratio
    Dividend Rate
    Dividend Yield
    1 Year High$6.37
    1 Year Low$1.89
    Open
    High
    Low

    Buy any stock with any amount of money.

    Download the App
    Download the app